Stryker Corporation $SYK Holdings Raised by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its stake in shares of Stryker Corporation (NYSE:SYK) by 47.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,638 shares of the medical technology company’s stock after acquiring an additional 2,148 shares during the period. Chicago Partners Investment Group LLC’s holdings in Stryker were worth $2,186,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of SYK. Vanguard Group Inc. grew its stake in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares in the last quarter. State Street Corp increased its position in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Stryker in the 4th quarter valued at approximately $1,822,272,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock worth $100,659,489 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on SYK. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Citigroup cut their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, BMO Capital Markets assumed coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $392.52.

Stryker Stock Down 6.1%

SYK opened at $311.27 on Wednesday. The firm has a market cap of $119.33 billion, a P/E ratio of 36.03, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business has a 50 day moving average price of $310.79 and a 200 day moving average price of $337.37. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.